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S U M M A R Y
Tuberculosis (TB) has been recognized as an important cause of morbidity and mortality in pregnancy for
nearly a century, but research and efforts to roll out comprehensive TB screening and treatment in high-
risk populations such as those with a high prevalence of HIV or other diseases of poverty, have lagged
behind similar efforts to address HIV infection in pregnancy and the prevention of mother-to-child-
transmission. Immunological changes during pregnancy make the activation of latent TB infection or de
novo infection more likely than among non-pregnant women. TB treatment in pregnancy poses several
problems that have been under-researched, such as contraindications to anti-TB and anti-HIV drugs and
potential risks to the neonate, which are particularly important with respect to second-line TB
treatment. Whilst congenital TB is thought to be rare, data from high HIV burden settings suggest this is
not the case. There is a need for more studies screening for TB in neonates and observing outcomes, and
testing preventative or curative actions. National tuberculosis control programmes (NTPs) should work
with antenatal and national HIV programmes in high-burden populations to provide screening at
antenatal clinics, or to establish functioning systems whereby pregnant women at high risk can drop in
to routine NTP screening stations.
 2014 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/3.0/).
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Worldwide, an estimated 900 million women have a latent
Mycobacterium tuberculosis infection (LTBI), and pregnant women
with LTBI are more likely to progress to developing active
tuberculous disease than men. It has long been observed by
obstetricians that pregnancy is associated with a more prevalent
onset of active tuberculosis (TB) and also more rapid progression of
TB disease compared with the non-pregnant state. The earliest
publications on this topic date back to 1922, when Dr David
Stewart, a medical superintendent of a women’s TB sanatorium,
wrote two articles in the Canadian Medical Association Journal on
TB in pregnancy.1,2 Looking past the very archaic writing style of
this early medical literature, from a time when pregnant women
admitted to a sanatorium faced the prospect of forced abortion (or* Corresponding author. Tel.: +260 97 4044708.
E-mail address: matthew.bates@ucl.ac.uk (M. Bates).
http://dx.doi.org/10.1016/j.ijid.2014.12.014
1201-9712/ 2014 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).even hysterectomy) in addition to the regular tortures then
accepted as soundly evidenced TB treatment, these early TB
practitioners, with their extensive experience of seeing thousands
of patients, made some valuable observations that are true to this
day: (1) both pregnancy and TB can have adverse effects on each
other and are linked with poor outcomes; (2) outcomes are
variable and extremely difﬁcult to predict early in pregnancy, and
management decisions should be made on a case-by-case basis;
and (3) for all populations, there should be special provision made
for pregnant women with TB.
This last point seems to have been forgotten by many. Whilst
there have been colossal investments in maternal HIV diagnosis
and treatment at the epicentre of the modern day TB pandemic
(Sub-Saharan Africa), with interventions rolled out across the
region improving both maternal and neonatal health, the same
attention has not been given to maternal TB, despite the well-
established epidemiological links between TB and HIV. Only 44% of
countries have World Health Organization (WHO)-compliant
guidelines for antiretroviral therapy (ART) in pregnant women.3ciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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action with respect to TB diagnosis and treatment during
pregnancy. Treating TB in HIV-infected pregnant women poses
huge challenges because of overlapping toxicities, side effects, pill
burden, changes in tolerability, and the pharmacokinetics of drugs.
Rifampicin, a ﬁrst-line TB drug, induces liver enzymes and alters
the metabolism of all antiretrovirals recommended for use during
pregnancy. There is a lack of data on all these factors and their
inﬂuence on the treatment outcomes of TB and HIV in pregnancy.
2. Prevalence of TB in pregnancy
The recently published WHO Tuberculosis Report for
2014 states that in 2013 there were an estimated 3.3 million
cases among women, with 510 000 deaths; a third of these women
were co-infected with HIV.4 The report does not mention the word
‘pregnancy’ or ‘pregnant’, indicative of the fact that most countries
do not screen routinely for TB in pregnancy nor do they report the
pregnancy status of female TB cases.5 The symptoms of TB overlap
considerably with those of pregnancy, and one South African study
has shown that the sensitivity of clinical screening for TB among
pregnant women is as low as 28%.6 This shows that without active
screening and case ﬁnding programmes among pregnant women,
we can never hope to reach sufﬁcient numbers of cases diagnosed
and treated.
A review of the available data suggested that the prevalence of
active TB among pregnant women ranges from 0.06% to 0.25% in
low-burden countries. In high-burden countries, rates of between
0.07% and 0.5% were found among HIV-negative women, and
between 0.7% and 11% among HIV-positive women.5 In a recent
epidemiological modelling study, Sugarman et al. estimated that
there may have been 216 500 (95% uncertainty range 192 000–
247 000) active TB cases among pregnant women globally in 2011,
with the highest case burden (41.3% of cases) in the WHO African
region.7
Large birthing centres represent a great opportunity for active
case ﬁnding. A recent evaluation of the Xpert MTB/RIF assay among
both obstetric and gynaecological admissions with suspected TB
found culture-proven TB in 27.7% of suspected cases.8 This TB
burden among maternal admissions with suspected TB was
comparable to that among all adult admissions at the same centre,
where active TB was diagnosed in 10% of adult admissions able to
produce a sputum specimen in whom TB was not suspected on
admission, making inpatients potentially a higher risk group for
missed TB infections than prisoners, refugees, and other well-
publicized groups.9,10 In the context of maternal HIV infection, and
also HIV-negative women from high TB burden communities, the
WHO prudently recommends standardized TB screening in
antenatal clinics.11 However, there is a general consensus that
the uptake of this guidance has been poor.5,8,12
3. Effects on immunity
Women are at increased risk of TB during pregnancy,13,14 and it
is commonly assumed that immunological changes associated
with pregnancy present an opportunity for mycobacterial infection
or re-activation. In the late stages of pregnancy, a whole range of
modiﬁcations in immune correlates have been observed. With
respect to cellular immunity, increased levels and activity of
phagocytes and plasmacytoid dendritic cells have been reported,
with down-regulated natural killer (NK) cell cytotoxicity by
progesterone-induced blocking factor and interleukin (IL)-10,
and also a decrease in interferon gamma (IFN-g) production,
indicting a generally suppressed innate cellular response.15,16
Adaptive cellular responses have also been evaluated, showing
that Th1 cytokines (IFN-g and IL-12) are down-regulated;however, reports on whether Th2 responses are modulated in
pregnancy have been conﬂicting.15,16 Observed changes in
humoral immunity include increased levels of complement
proteins and acute phase reactants, and also increased T-cell-
dependent immunoglobulin production.15,16 Pregnant women
who are HIV-positive and have LTBI are more likely to progress
to active TB disease.
4. TB as a cause of maternal deaths
Maternal mortality is high among women co-infected with HIV
and TB,17 and TB is associated with increased mortality both during
pregnancy and postpartum.14 Over 50% of pregnant women who
die of TB during pregnancy and postpartum are HIV-positive. A
medical record review of maternal mortality in Zambia dating to
the pre-nevirapine era, documented TB as a cause of death in 25%
of HIV-negative versus 32% of HIV-positive mothers.18–20 More
recent reviews or verbal autopsies of maternal deaths in Kenya and
South Africa have recorded death as being directly attributable to
TB in up to 20% of HIV-positive pregnant women.21,22 However,
post-mortem studies among the general population have shown
that medical record reviews and verbal autopsies grossly
underestimate the burden of TB as a cause of death.23,24
There has been just one post-mortem study undertaken in
Africa on maternal deaths, and this study identiﬁed TB as a cause of
death in 12.9% of deaths overall and 27.7% of deaths among HIV-
infected women.25 Such studies are the exception not the rule, and
so for the most part we must rely on comprehensive record reviews
to monitor changes in the burden of TB deaths over time. In South
Africa the prevalence of non-obstetric infectious causes of death
has increased steadily over the last two decades, concurrently with
the HIV pandemic, so that as of 2007, infections such as TB,
pneumonia, meningitis, and malaria accounted for 47% of all
maternal deaths as reviewed.26 Many record reviews have
highlighted serious shortcomings in how we record causes of
death, with ‘HIV/AIDS’ often being treated as a mutually exclusive
cause of death, with separate categories for TB and other
opportunistic infections. Consistent recording of maternal deaths
is challenging due to the varied obstetric and non-obstetric causes
that may present as co-morbidities.
5. Effects of maternal TB infection and treatment on the
neonate
It has long been known that a few neonates born to mothers
who have active TB disease will contract TB congenitally.
Congenital TB may be subclinical or associated with a range of
birth defects.27 This has been little studied at the centre of the HIV/
TB pandemic in Sub-Saharan Africa, but one study of 107 pregnant
South African women diagnosed with active TB (50% with
extrapulmonary or disseminated infection) documented seven
perinatal deaths, with an adjusted perinatal mortality rate
attributable to TB of 65.2/1000 among HIV-infected women.28
Sixty-six percent of neonates were of low birth weight, compared
to a hospital population rate of 22%.
Another South African study detected TB in 9% of infants born to
mothers with active TB, and found maternal TB to be strongly
associated with both maternal and neonatal mortality.14 Epidemi-
ological methods suggest a lower rate of vertical transmission, but
these rely on routine culture returns and it is highly likely that
many neonates born to mothers with TB are either not screened or
may develop symptoms after discharge.29
A Mexican study found maternal TB to be associated with
increased morbidity, lower birth weight, and an increased risk
of death.30 Studies from South Asia have linked TB during
pregnancy to poor perinatal outcomes, including low birth weight,
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maternal morbidity and mortality.32,34 Even in low-burden
countries such as the UK, where TB during pregnancy is much
less prevalent (62/100 000 pregnancies), it is still associated with
low birth weight.35
A recent South African study of 97 HIV-infected women, half of
whom had TB, found just one case of mother-to-child-transmission
of HIV, and so could not prove that in the context of HIV, maternal
TB has any inﬂuence on mother-to-child transmission of HIV,
although women with TB had a higher HIV viral load at birth and
had on average initiated ART earlier.36
6. Multidrug-resistant TB and pregnancy
Whilst the use of rifampicin and isoniazid in pregnancy have
not been associated with major toxic effects on the mother or
neonate, treatment options for multidrug-resistant TB (MDR-TB) in
pregnancy are limited. Second-line TB drugs carry greater risks to
both mother and child. Most have proven foetal toxicity from
animal studies and are also present in breast milk, posing a risk to
the infant; nevertheless the potential beneﬁts could justify
treatment depending on the speciﬁc case.5
Case-controlled observational studies to assess maternal out-
comes are logistically challenging for MDR-TB, since the case
burden will be low and laboratory capacity to detect MDR-TB is
poor. There have been several case studies published; some have
documented no adverse perinatal outcomes,37–39 while others
have recorded growth restriction40 and congenital defects.41 Such
case studies must be interpreted with extreme caution, however,
as there are a range of potential risk factors for neonatal morbidity
and mortality that might be epidemiologically linked with MDR-
TB.
Second-line TB drugs used to treat MDR-TB, such as aminogly-
cosides, are ototoxic and nephrotoxic for both the mother and the
foetus. Quinolones have teratogenic potential and cause skeletal
deformities. There are no safety data from human studies for the
new TB drugs bedaquiline and delamanid, limiting their usefulness
in treating pregnant women with MDR-TB. The WHO now
recommends isoniazid preventative therapy (IPT) in HIV-infected
individuals. A study from Botswana found a 6–12-month course of
IPT to be safe in pregnant women, and neither IPT nor ART was
associated with poor outcomes.42
7. Extrapulmonary TB and pregnancy
The literature is abound with case series and individual reports
of extrapulmonary TB (EPTB) in pregnancy, so much so that, taken
with the proven burden of pulmonary TB in pregnancy, it is
reasonable to suggest that EPTB will account for a signiﬁcant
minority of cases of TB in pregnancy. Reported outcomes are
frequently better in high-income populations,43,44 but many cases
are diagnosed late, as the symptoms may be confused with those of
other possible conditions; some cases may even be diagnosed
retrospectively after identiﬁcation of neonatal TB.45,46
Reported presentations include, but are not restricted to,
papulonecrotic tuberculids,47 TB spine,48,49 meningitis,50 primitive
caeco-appendicular TB,51 genital TB as a possible cause of ectopic
pregnancy,52,53 pericarditis,54 hemoptysis,55,56 and peritoneal
TB.57–59 Foetal outcomes range from being completely asymptom-
atic, to serious congenital abnormalities, and even a spontaneous
abortion with TB histology in both placenta and foetus.60
8. Conclusions
The study of TB in pregnancy is confounded by overlapping
clinical presentations of TB with normal pregnancy-relatedconditions. As per the WHO recommendations for microbiological
screening of TB in pregnancy for high HIV and TB-burden antenatal
clinics, National TB Programmes (NTPs) should make a concerted
effort to capture pregnancy-associated TB and to follow-up on
perinatal outcomes. Collected data should then be analysed and
published to better inform guidelines for TB diagnosis and
treatment in pregnancy. This is of particular importance with
respect to EPTB and MDR-TB. Such cases should be reported to the
NTP with immediate effect and efforts made to follow-up these
cases, providing the best available care and also recording
outcomes.
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